XLXiang Lei

Xiang Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiang Lei has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Hongcai Shang

    Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

    4 shared publications
  • Bai Chang

    Tianjin Medical University Chu Hsien-I Memorial Hospital, China

    1 shared publication
  • Baoshan Liu

    The General Hospital, Tianjin Medical University, Anshan Road, Heping District, Tianjin 300070, China

    1 shared publication
  • Chengyu Li

    Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Lane, Dongcheng District, Beijing, 100700, China

    1 shared publication
  • Chunxiang Liu

    Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    1 shared publication
  • Hongbo Cao

    Tianjin Institute of Clinical Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, China Center for Evidence-Based Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    1 shared publication

Latest Publications

  • Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials

    by Chengyu Li, Ping Wang, Li Zhang, Min Li, Xiang Lei, Si Liu, Zhiqiao Feng, Yongming Yao, Bai Chang, Baoshan Liu, et al.


    • 1 September 2015
      • Vol. 40  (18) , 3693-6

    [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].

    by Wen-Ke Zheng, Zhi Liu, Xiang Lei, Ran Tian, Rui Zheng, Nan Li, Jing-Tian Ren, Xiao-Xi Du, Hong-Cai Shang

    The safety of Chinese patent medicine has become a focus of social. It is necessary to carry out work on post-marketing clinical safety evaluation for Chinese patent medicine. However, there have no criterions to guide the related research, it is urgent to set up a model and method to guide the practice for related research. According to a series of clinical research, we put forward some views, which contained clear and definite the objective and content of clinical safety evaluation, the work flow should be determined, make a list of items for safety evaluation project, and put forward the three level classification of risk control. We set up a model of post-marketing clinical safety evaluation for Chinese patent medicine. Based this model, the list of items can be used for ranking medicine risks, and then take steps for different risks, aims to lower the app:ds:risksrisk level. At last, the medicine can be managed by five steps in sequence. The five steps are, collect risk signal, risk recognition, risk assessment, risk management, and aftereffect assessment. We hope to provide new ideas for the future research.


    • 1 May 2015
      • Vol. 40  (10) , 2050-3

    [Systematic economic assessment and quality evaluation for traditional Chinese medicines].

    by Xiao Sun, Li-Ping Guo, Hong-Cai Shang, Ming Ren, Xiang Lei

    To learn about the economic studies on traditional Chinese medicines in domestic literatures, in order to analyze the current economic assessment of traditional Chinese medicines and explore the existing problems. Efforts were made to search CNKI, VIP, Wanfang database and CBM by computer and include all literatures about economic assessment of traditional Chinese medicines published on professional domestic journals in the systematic assessment and quality evaluation. Finally, 50 articles were included in the study, and the systematic assessment and quality evaluation were made for them in terms of titles, year, authors' identity, expense source, disease type, study perspective, study design type, study target, study target source, time limit, cost calculation, effect indicator, analytical technique and sensitivity analysis. The finally quality score was 0.74, which is very low. The results of the study showed insufficient studies on economics of traditional Chinese medicines, short study duration and simple evaluation methods, which will be solved through unremitting efforts in the future.


  • Open Access

    Use of comparative effectiveness research for similar Chinese patent medicine for angina pectoris of coronary heart disease: a new approach based on patient-important outcomes

    by Hongbo Cao, Jingbo Zhai, Wei Mu, Xiang Lei, Hongxia Cao, Chunxiang Liu, Hongcai Shang

    The practice of traditional Chinese medicine (TCM) has a profound history in many Asian countries. TCM syndrome is a set of characteristic physical signs and symptoms shared by a group of patients. Syndrome diagnosis and treatment assignment according to the identified TCM syndrome is a long-held practice of Chinese medicine. Owing to its distinctive way of interpreting illness and administering care, medical practitioners not well educated in TCM theories and practices are generally incapable of giving out prescriptions for Chinese patent drugs. Currently, the existence of a multitude of Chinese patent drugs marked with largely identical indications is further complicating this situation. In this multicenter, randomized, controlled, double-blind, double-dummy clinical trial, in which we will use the comparative effectiveness research method, we will compare the efficacy of two commonly used Chinese patent medicines for angina patients diagnosed with qi deficiency and blood stasis syndrome. A total of 160 patients will be recruited and randomly assigned to receive either (1) QiShenYiQi dripping pills, Tongxinluo placebo and routine medication or (2) Tongxinluo capsules, QiShenYiQi placebo and routine medication. These treatment regimens will be carried out for 4 weeks, followed by a 10-day washout period and a 4-week crossover phase in which the treatments in the two patient groups will be exchanged. Patients will be allowed to choose symptoms that matter most to them and will be grouped accordingly. Patient-reported outcomes such as the Seattle Angina Questionnaire score and the 15-point Likert scale score will be measured and reported. The minimally clinical important difference will be calculated and used for efficacy assessment, and correspondence analysis will be performed to identify the best indications for each drug. The goal of the study is to establish a methodology for the precise identification of the characteristic indications for which a Chinese patent drug is most effective. The findings of this study will inform the practicality of the proposed evaluation method. Chinese clinical trials register Chi CTRTTRCC13003732